scPharmaceuticals
SCPH
SCPH was delisted on the 6th of October, 2025.
41 hedge funds and large institutions have $45.8M invested in scPharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 14 increasing their positions, 5 reducing their positions, and 10 closing their positions.
180% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 5
30% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 10
8% more funds holding
Funds holding: 38 → 41 (+3)
1.23% less ownership
Funds ownership: 44.88% → 43.65% (-1.2%)
56% less capital invested
Capital invested by funds: $103M → $45.8M (-$57.4M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIC
AWM Investment Company
New York
|
+$1.98M |
| 2 |
BlackRock
New York
|
+$613K |
| 3 |
Morgan Stanley
New York
|
+$542K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$306K |
| 5 |
CG
Colony Group
Boston,
Massachusetts
|
+$238K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.79M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.48M |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$692K |
| 4 |
D.E. Shaw & Co
New York
|
-$545K |
| 5 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
-$501K |
SCPH Hedge Fund Activity: Q2 2018 in Review
41 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in scPharmaceuticals (SCPH) for Q2 2018, worth a combined $45.8M — down 56% from $103M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new SCPH positions and 10 closed out — a net gain of 3 holders — while 14 added to existing stakes and 5 trimmed.
The largest buyer was AWM Investment Company, adding an estimated $1.98M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $3.79M sold.
- 41 institutional investors held scPharmaceuticals (SCPH) as of Q2 2018, up from 38 in Q1 2018.
- Funds reported $45.8M of scPharmaceuticals stock for Q2 2018, down 56% quarter-over-quarter.
- 13 funds opened new scPharmaceuticals positions in Q2 2018 and 10 closed out, a net change of +3 holders.
- The largest scPharmaceuticals buyer in Q2 2018 was AWM Investment Company, an estimated $1.98M added.
- The largest scPharmaceuticals seller in Q2 2018 was T. Rowe Price Associates, an estimated $3.79M sold.
Based on aggregated 13F filings for Q2 2018.